Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
15 May 2017
Notification of Major Interest in Mediclinic International plc shares
1. Identity of the issuer or the underlying issuer |
MEDICLINIC INTERNATIONAL PLC |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
X |
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
|
|
||
3. Full name of person(s) subject to the |
PUBLIC INVESTMENT CORPORATION SOC LIMITED |
|||
4. Full name of shareholder(s) |
N/A |
|||
5. Date of the transaction and date on |
11 May 2017 |
|||
6. Date on which issuer notified: |
12 May 2017 |
|||
7. Threshold(s) that is/are crossed or |
8% |
|||
8. Notified details: |
|||||||||||||||||
A: Voting rights attached to shares |
|||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
|||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights |
|||||||||||||
Direct |
Direct |
Indirect |
Direct |
Indirect |
|||||||||||||
GB00B8HX8Z88 |
58 705 799 |
|
59 447 726 |
|
|
8.064% |
|
||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
B: Qualifying Financial Instruments |
|||||||||||||||||
Resulting situation after the triggering transaction |
|||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
|||||||||||||
NONE |
N/A |
N/A |
N/A |
N/A |
|||||||||||||
|
|||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments |
|||||||||||||||||
Resulting situation after the triggering transaction |
|||||||||||||||||
Type of financial |
Exercise price |
Expiration date |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights
|
||||||||||||
|
|
|
|
|
Nominal |
Delta |
|||||||||||
|
|
||||||||||||||||
|
|||||||||||||||||
Total (A+B+C) |
|||||||||||||||||
Number of voting rights |
Percentage of voting rights |
||||||||||||||||
59 447 726 |
8.064% |
||||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
N/A |
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
N/A |
|
11. Number of voting rights proxy holder will cease |
N/A |
|
12. Date on which proxy holder will cease to hold |
N/A |
|
|
||
|
|
|
14. Contact name: |
DEVILLIERS MAKONKO |
|
15. Contact telephone number: |
012 742 3578 |
|
Mediclinic's primary listing is on the Main Market of the LSE, with secondary listings on the JSE in South
Africa and on the NSX in Namibia.
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
For further information please contact:
Mediclinic International plc
James Arnold, Head of Investor Relations
Capita Company Secretarial Services Limited
Victoria Dalby
+44 (0)207 954 9600